Foresite Capital, a multi-stage healthcare and life sciences investment firm, and TCGX, a science-driven investment firm, led a $105m financing round in CG Oncology, an oncolytic immunotherapy company, with participation from Avidity Partners, BVF Partners and Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporation and RA Capital Management. “We are excited to welcome leading life science investors who share our vision of developing cutting-edge therapeutics addressing unmet medical needs in bladder cancer. Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and in combination studies and we are encouraged to see our treatments get closer to being available to bladder cancer patients worldwide,” Arthur Kuan, CG Oncology CEO.